Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 9:20 AM EDTCompany ParticipantsSean McCarthy ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and ...

The partnership brings together CytomX’s biologic masking technology and Regeneron’s expertise in bispecific antibodies.

Bristol-Myers Squibb (BMS) is paying CytomX Therapeutics $200 million upfront to add up to eight new candidates to their existing Probody™ therapeutics collaboration. CytomX could potentially receive ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CytomX Therapeutics, the Probody™ therapeutics company, today announced the presentation of new data demonstrating preclinical proof of concept of the ...

Bristol-Myers Squibb (BMS) is back for seconds, dropping $200 million for up to eight more “probody” drug candidates from CytomX Therapeutics. Announced Monday, the deal also outlines a potential ...

AbbVie will co-develop and co-commercialize at least one and possibly more CytomX Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). The cancer therapy collaboration ...

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that its partner Bristol Myers Squibb presented preclinical data from BMS-986249 ...

A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy. This is an ASCO Meeting Abstract from the ...

Comparative analysis of durable responders on immune checkpoint inhibitors (ICI) versus other systemic therapies: A meta-analysis of phase III trials. This is an ASCO Meeting Abstract from the 2018 ...